We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
IMFINZI (AstraZeneca Pty Ltd)
Product name
IMFINZI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
232 (255 working days)
Active ingredients
durvalumab
Registration type
EOI
Indication
Endometrial cancer
IMFINZI in combination with carboplatin and paclitaxel, followed by IMFINZI monotherapy, is indicated for the first-line treatment of patients with primary advanced or recurrent endometrial cancer.